SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
GEVA was delisted on the 22nd of June, 2015.
115 hedge funds and large institutions have $3.53B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2014 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 46 increasing their positions, 37 reducing their positions, and 21 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
32% more capital invested
Capital invested by funds: $2.68B → $3.53B (+$854M)
24% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 37
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
0% more funds holding
Funds holding: 115 → 115 (0)
51% less call options, than puts
Call options by funds: $31.3M | Put options by funds: $63.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$78.6M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$36.4M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$19.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$26.4M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$8.57M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$7.21M |
| 4 |
TCP
Tourbillon Capital Partners
New York
|
-$4.98M |
| 5 |
D.E. Shaw & Co
New York
|
-$4.82M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARC
126
Absolute Return Capital
Boston,
Massachusetts
| – | -$1.07M | -12,875 | Closed |
|
127
SG Americas Securities
New York
| – | -$802K | -9,662 | Closed |
|
|
HH
128
HWG Holdings
Houston,
Texas
| – | -$682K | -8,219 | Closed |
|
|
PCM
129
Prelude Capital Management
New York
| – | -$551K | -6,638 | Closed |
|
|
BACM
130
Blue Arrow Capital Management
New York
| – | -$498K | -6,000 | Closed |
|
131
Jane Street
New York
| – | -$378K | -4,567 | Closed |
|
|
HI
132
HBK Investments
Dallas,
Texas
| – | -$266K | -3,200 | Closed |
|
|
QT
133
Quantbot Technologies
New York
| – | -$16K | -200 | Closed |
|
134
Millennium Management
New York
| – | -$8.51K | -100 | Closed |
|
|
TRCT
135
Tower Research Capital (TRC)
New York
| – | -$2K | -29 | Closed |
|
136
M&T Bank
Buffalo,
New York
| – | -$2K | -21 | Closed |
|
GEVA Hedge Fund Activity: Q2 2014 in Review
115 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q2 2014, worth a combined $3.53B — up 32% from $2.68B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new GEVA positions and 21 closed out — a net gain of 1 holder — while 46 added to existing stakes and 37 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $78.6M. The largest seller was Deerfield Management, exiting entirely with an estimated $26.4M sold.
- 115 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q2 2014, unchanged from Q1 2014.
- Funds reported $3.53B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q2 2014, up 32% quarter-over-quarter.
- 22 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q2 2014 and 21 closed out, a net change of +1 holder.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q2 2014 was Fidelity Investments, an estimated $78.6M added.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q2 2014 was Deerfield Management, an estimated $26.4M sold.
Based on aggregated 13F filings for Q2 2014.